Cambridge, UK, 7th May 2025 / Domainex, a multi-award-winning, integrated drug discovery contract research organisation (CRO), has formally announced the appointment of Hayley French as its new Chief Executive Officer.
Hayley French is a qualified attorney with a background in microbiology and significant experience in the life sciences sector. She possesses a proven track record of fostering growth and innovation, having held leadership positions in multiple pharmaceutical and biotechnology organisations. Her areas of expertise include strategic development, business operations, and commercialisation.
“We are excited to welcome Hayley to Domainex,” remarked Eddy Littler, Chairman of Domainex. “Her profound understanding of the biotechnology landscape, strategic vision, and exemplary leadership skills render her the ideal individual to steer Domainex through its next stage of growth. We are confident that under her stewardship, Domainex will continue to deliver exceptional value to its clients and partners.”
Prior to her appointment at Domainex, Hayley occupied several senior leadership roles, including Chief Executive Officer of Apitope International NV before its acquisition by Worg Pharmaceuticals. She has also held legal positions related to pharmaceutical and biotechnology transactions at Novartis and Bird & Bird in London, in addition to serving as the Head of Legal Affairs at CAMR in the UK. Hayley commenced her career at UCL Ventures.
“I am honoured to join Domainex and lead this talented team,” commented Hayley. “Domainex is renowned for its innovative approach to drug discovery and its unwavering commitment to delivering high-quality results. I am eager to collaborate with the Domainex team to build upon this strong foundation and drive further success.”
Hayley's appointment is effective immediately, and she will be based at Domainex's headquarters in Cambridge, UK. Eddy Littler, who has been serving as Chief Executive Officer, will revert to his position as non-executive Chairman.
ENDS
For further information, please contact:
Sciad Communications, Media Relations
Juliette Craggs/Maria Taylor
T: +44 (0)20 3405 7892
E: domainex@sciad.com
Notes to editors
About Domainex
Domainex is a multi-award-winning, integrated drug discovery service partner, committed to driving discovery and delivering high-quality leads for life science organisations around the world. Our world-leading experts accelerate research projects by combining a proactive, problem-solving approach with cutting-edge technologies.
Domainex combines scientific rigour with a collaborative approach to drive progress in complex drug discovery programmes. With deep expertise across a wide range of target classes and therapeutic areas, and a core focus on the hit identification and hit-to-lead stages, we deliver high-quality results that support confident, timely decision-making for our partners.
Operating from our state-of-the-art research hub in Cambridge, UK, we provide tailored discovery solutions from target expression through to the identification of pre-clinical candidates. Our contributions to drug discovery partnerships have underpinned over 60 patent applications for novel drug candidates, reflecting our trusted role in advancing innovative research.
Further information about Domainex and our award-winning lead discovery services can be found at www.domainex.co.uk.